Daratumumab-²²⁵Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors.

ABSTRACT: Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocytosis, and T-cell activation. However, not all patients respond to daratumumab therapy and management of MM remains challenging. Radioimmunotherapy with alpha particle-emitting radionuclides represents a promising approach to significantly enhance the potency of therapeutic antibodies in cancer treatment. Here we report the results of mechanistic and feasibility studies using daratumumab radiolabeled with an alpha-emitter ²²⁵Actinium for therapy of MM. CD38-positivelymphoma Daudi cell l

SUBMITTER: Dawicki W 

PROVIDER: S-EPMC6682347 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature